Danicopan

Chemical formula: C₂₆H₂₃BrFN₇O₃ Molecular mass: 579.103 g/mol PubChem compound: 118323590

Therapeutic indications

Danicopan is indicated for:

Paroxysmal nocturnal haemoglobinuria in patients who have residual haemolytic anaemia

Population group: only adults (18 years old or older)

Danicopan is indicated as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

150 mg 3 times daily and after a minimum of 4 weeks 150-200 mg 3 times daily

Contraindications

Danicopan is contraindicated in the following cases:

Lactation

Patients with unresolved Neisseria meningitidis infection at treatment initiation

Meningococcal infectious disease

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.